> Detailanzeige

de Gelder, Rianne; van As, Elisabeth; Tilanus‐Linthorst, Madeleine M.A.; Bartels, Carina C.M.; Boer, Rob; Draisma, Gerrit; de Koning, Harry J.

Breast cancer screening: Evidence for false reassurance?

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Breast cancer screening: Evidence for false reassurance?
  • Beteiligte: de Gelder, Rianne; van As, Elisabeth; Tilanus‐Linthorst, Madeleine M.A.; Bartels, Carina C.M.; Boer, Rob; Draisma, Gerrit; de Koning, Harry J.
  • Erschienen: Wiley, 2008
  • Erschienen in: International Journal of Cancer
  • Sprache: Englisch
  • DOI: 10.1002/ijc.23540
  • ISSN: 0020-7136; 1097-0215
  • Schlagwörter: Cancer Research ; Oncology
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:title>Abstract</jats:title><jats:p>Tumour stage distribution at repeated mammography screening is, unexpectedly, often not more favourable than stage distribution at first screenings. False reassurance, <jats:italic>i.e</jats:italic>., delayed symptom presentation due to having participated in earlier screening rounds, might be associated with this, and unfavourably affect prognosis. To assess the role of false reassurance in mammography screening, a consecutive group of 155 breast cancer patients visiting a breast clinic in Rotterdam (The Netherlands) completed a questionnaire on screening history and self‐observed breast abnormalities. The length of time between the initial discovery of breast abnormalities and first consultation of a general practitioner (“symptom–GP period”) was compared between patients with (“screening group”) and without a previous screening history (“control group”), using Kaplan–Meier survival curves and log‐rank testing. Of the 155 patients, 84 (54%) had participated in the Dutch screening programme at least once before tumour detection; 32 (38%) of whom had noticed symptoms. They did not significantly differ from control patients (<jats:italic>n</jats:italic> = 42) in symptom–GP period (symptom–GP period ≥30 days: 31.2% in the symptomatic screened group, 31.0% in the control group; <jats:italic>p</jats:italic> = 0.9). Only 2 out of 53 patients (3.8%) with screen‐detected cancer had noticed symptoms prior to screening, reporting symptom–GP periods of 2.5 and 4 years. The median period between the first GP‐ and breast clinic visit was 7.0 days (95% C.I. 5.9–8.1) in symptomatic screened patients and 6.0 days (95% C.I. 4.0–8.0) in control patients. Our results show that false reassurance played, at most, only a minor role in breast cancer screening. © 2008 Wiley‐Liss, Inc.</jats:p>
  • Zugangsstatus: Freier Zugang